Sanofi and Genzyme Congratulate the 2012 Schwartz Center Compassionate Caregiver Award Winner

  Sanofi and Genzyme Congratulate the 2012 Schwartz Center Compassionate
  Caregiver Award Winner

Business Wire

CAMBRIDGE, Mass. -- November 09, 2012

Sanofi (EURONEXT: SAN and NYSE: SNY) and Genzyme, a Sanofi Company, today
congratulated John Zawacki, MD, of UMass Memorial Medical Center in Worcester,
Massachusetts, the recipient of the 2012 Schwartz Center Compassionate
Caregiver Award, for his display of extraordinary compassion in caring for
patients and families. Sanofi Oncology and Genzyme were the co-sponsors of the
award, which was announced Thursday, November 8th, at the 17th Annual Kenneth
B. Schwartz Compassionate Healthcare Dinner at the Boston Convention Center.

Dr. Zawacki is a gastroenterologist who cares for patients with Crohn’s
disease, ulcerative colitis and irritable bowel syndrome. He has also taught
and mentored hundreds of medical students, residents and fellows, telling
them, “As long as you share your feelings and have good intentions, the words
will come. It [being a doctor] is not a scripted experience.”

The Schwartz Center for Compassionate Healthcare, a nonprofit organization
dedicated to strengthening the relationship between patients and their
healthcare providers, established the award in 1999 to honor healthcare
providers who practice compassionate care, which includes effective
communication, emotional support, mutual trust and respect, involving patients
and families in healthcare decisions, and treating patients as people.

Debasish Roychowdhury, Head of Sanofi Oncology, and David Meeker, President
and CEO of Genzyme, warmly praised Dr. Zawacki and this year’s other nominees
for embodying Ken Schwartz’s deeply held belief that what matters most during
an illness is the human connection between patientsand their caregivers.

The Schwartz Center for Compassionate Healthcare (
was founded in 1995 by Ken Schwartz, a Boston healthcare attorney who died of
lung cancer at the age of 40 and found that what mattered to him most as a
patient was the compassionate care he received from his caregivers. He
established the Schwartz Center just days before his death to ensure that all
patients and families receive compassionate care.

About Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies
for patients affected by rare and debilitating diseases for over 30 years. We
accomplish our goals through world-class research and with the compassion and
commitment of our employees. With a focus on rare diseases and multiple
sclerosis, we are dedicated to making a positive impact on the lives of the
patients and families we serve. That goal guides and inspires us every day.
Genzyme’s portfolio of transformative therapies, which are marketed in
countries around the world, represents groundbreaking and life-saving advances
in medicine. As a Sanofi company, Genzyme benefits from the reach and
resources of one of the world’s largest pharmaceutical companies, with a
shared commitment to improving the lives of patients. Learn more at

About Sanofi Oncology

Based in Cambridge, Massachusetts, USA and Vitry-sur-Seine, France, Sanofi
Oncology is dedicated to translating science into effective therapeutics that
address unmet medical needs for cancer and organ transplant patients. Starting
with a deep understanding of the disease and the patient, Sanofi Oncology
employs innovative approaches to drug discovery and clinical development, with
the ultimate goal of bringing the right medicines to the right patients to
help them live healthier and longer lives. We believe in the value of
partnerships that combine our internal scientific expertise with that of
industry and academic experts. Our portfolio includes 10 marketed products and
more than 15 investigational compounds in clinical development, including
small molecules and biological agents.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients’ needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).

Photos/MultimediaGallery Available:



Genzyme Communications
Lori Gorski, 617-768-9344
Sanofi Oncology Communications
Lauren Musto, 617-768-1993
Press spacebar to pause and continue. Press esc to stop.